Avoro Capital Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-2,485,272
| Closed | -$9.2M | – | 66 |
|
|
2017
Q4 | $9.2M | Buy |
2,485,272
+664,024
| +36% | +$2.72M | 0.6% | 27 |
|
|
2017
Q3 | $7.45M | Hold |
1,821,248
| – | – | 0.58% | 32 |
|
|
2017
Q2 | $6.77M | Hold |
1,821,248
| – | – | 0.85% | 28 |
|
|
2017
Q1 | $7.54M | Buy |
1,821,248
+900,000
| +98% | +$3.78M | 0.96% | 26 |
|
|
2016
Q4 | $3.97M | Sell |
921,248
-13,973
| -1% | -$90.3K | 0.8% | 26 |
|
|
2016
Q3 | $9.2M | Sell |
935,221
-22,233
| -2% | -$158K | 1.61% | 20 |
|
|
2016
Q2 | $5.42M | Buy |
957,454
+279,275
| +41% | +$1.9M | 1.2% | 22 |
|
|
2016
Q1 | $5.17M | Sell |
678,179
-8,333
| -1% | -$64.2K | 1.8% | 17 |
|
|
2015
Q4 | $9.14M | Sell |
686,512
-231,258
| -25% | -$3.98M | 3.15% | 12 |
|
|
2015
Q3 | $15.1M | Sell |
917,770
-18,397
| -2% | -$377K | 3.92% | 10 |
|
|
2015
Q2 | $21M | Buy |
936,167
+187,561
| +25% | +$2.97M | 5.79% | 5 |
|
|
2015
Q1 | $7.32M | Buy |
748,606
+250,000
| +50% | +$2.45M | 2.81% | 12 |
|
|
2014
Q4 | $5.68M | Buy |
+498,606
| New | +$5.41M | 3.85% | 9 |
|
Avoro Capital Advisors's CASC Position: Q1 2018 in Review
Avoro Capital Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 2,485,272 shares — an estimated $9.2M sold.
Avoro Capital Advisors first reported a position in CASC in Q4 2014 and held it in 13 quarters. The position peaked at $21M in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Avoro Capital Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Avoro Capital Advisors sold 2,485,272 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $9.2M.
- Avoro Capital Advisors first reported a position in Cascadian Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
- Avoro Capital Advisors's Cascadian Therapeutics, Inc. position peaked at $21M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Avoro Capital Advisors's 13F filing for Q1 2018, filed 15 May 2018.